Added to YB: 2026-09-14
Pitch date: 2026-09-10
WVE [neutral]
Wave Life Sciences, Inc.
Author Info
No bio for this author
Company Info
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health.
Market Cap
$947.8M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.45
P/E
-4.47
EV/Sales
7.66
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage Day 3 session 1 - Wave Life Sciences, Inc.
WVE (quick overview): Wave Life Sciences offers long-term RNA-platform optionality at a $4.81 share price, led by durable RNA editing for alpha-1 antitrypsin deficiency and an obesity program targeting fat reduction while preserving lean mass. FDA feedback on WVE-006’s Phase 3 path and upcoming multidose data are key near-term events, but both programs remain clinically and regulatorily unproven, and GSK’s departure leaves Wave with more development responsibility.
Read full article (2 min)